- Home
- PTGX
as 10-30-2025 9:33am EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Upcoming Earnings Alert:
Get ready for potential market movements as Protagonist Therapeutics Inc. PTGX prepares to release earnings report on 31 Oct 2025.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 4.0B | IPO Year: | 2016 |
| Target Price: | $78.11 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.80 | EPS Growth: | -70.73 |
| 52 Week Low/High: | $33.31 - $93.25 | Next Earning Date: | 10-31-2025 |
| Revenue: | $209,180,000 | Revenue Growth: | -34.45% |
| Revenue Growth (this year): | -85.29% | Revenue Growth (next year): | 142.86% |
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Waddill William D. | PTGX | Director | Oct 10 '25 | Sell | $78.53 | 12,000 | $979,480.00 | 13,130 | |
| Waddill William D. | PTGX | Director | Sep 22 '25 | Sell | $64.25 | 4,000 | $257,000.00 | 13,130 |
Latest Protagonist Therapeutics Inc. News
PTGX Breaking Stock News: Dive into PTGX Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals
MT Newswires
2 months ago
Leerink Partners Initiates Protagonist Therapeutics at Outperform With $73 Price Target
MT Newswires
2 months ago
Protagonist Says Johnson & Johnson Submits Application to EMA for Plaque Psoriasis Treatment
ACCESS Newswire
2 months ago
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
ACCESS Newswire
4 months ago
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Argus Research
4 months ago
PTGX: Lowering target price to $56.00
Insider Monkey
4 months ago
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
Insider Monkey
4 months ago
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Compare PTGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.